PF074 VEGF₁₆₅, Human, Recombinant

PF074
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability

      Overview

      Replacement Information

      Key Specifications Table

      Purity
      ≥95% by SDS-PAGE

      Pricing & Availability

      Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
      PF074-10UG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Plastic ampoule 10 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewRecombinant, human VEGF165 (a 165 amino acid splice varian of VEGF) expressed under serum-free conditions in Spodoptera frugiperda cells and purified via a proprietary sequential chromatrography methods. VEGF165 binds to the connective tissue growth factor (CTGF) and the resulting complex has no angiogenic activity. Degradation of CTGF by matrix metalloproteinases results in VEGF-induced angiogenesis during embryonic development and pathological disease states. The recombinant disulfide-linked homodimeric human VEGF is glycosylated and, thus, migrates as a ~42 kDa protein in SDS-PAGE under non-reducing conditions.
          Catalogue NumberPF074
          Brand Family Calbiochem®
          SynonymsVascular Permeability Factor
          References
          ReferencesHashimoto, G., et al. 2002. J. Biol. Chem. In Press.
          Soker, S., et al. 1998. Cell 92, 735.
          Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
          Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
          Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
          Brown, L., et al. 1992. Kidney International 42, 1457.
          Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275.
          Conn, G., et al. 1990. PNAS 87, 1323.
          Leung, D.W., et al. 1989. Science 246, 1306.
          Product Information
          FormLyophilized
          FormulationCarrier free.
          PreservativeNone
          Applications
          Data setup Error. Pagelet <collection_feature_application_id-PROLIF> not found.
          Application NotesProliferation Studies
          Biological Information
          Biological activityEC₅₀ of 1-6 ng/ml as determined by the dose dependent proliferation of human ubilical vein epithelial cells (HUVEC)
          Purity≥95% by SDS-PAGE
          Physicochemical Information
          ContaminantsEndotoxins: ≤100 pg/µg VEGF
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Dry Ice Only
          Toxicity Standard Handling
          Storage -20°C
          Avoid freeze/thaw Avoid freeze/thaw
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          VEGF₁₆₅, Human, Recombinant SDS

          Title

          Safety Data Sheet (SDS) 

          VEGF₁₆₅, Human, Recombinant Certificates of Analysis

          TitleLot Number
          PF074

          References

          Reference overview
          Hashimoto, G., et al. 2002. J. Biol. Chem. In Press.
          Soker, S., et al. 1998. Cell 92, 735.
          Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
          Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
          Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
          Brown, L., et al. 1992. Kidney International 42, 1457.
          Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275.
          Conn, G., et al. 1990. PNAS 87, 1323.
          Leung, D.W., et al. 1989. Science 246, 1306.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision16-September-2008 RFH
          SynonymsVascular Permeability Factor
          ApplicationProliferation Studies
          DescriptionRecombinant, human VEGF165 (a 165 amino acid splice varian of VEGF) expressed under serum-free conditions in Spodoptera frugiperda cells and purified via a proprietary sequential chromatrography methods. VEGF165 binds to the connective tissue growth factor (CTGF) and the resulting complex has no angiogenic activity. Degradation of CTGF by matrix metalloproteinases results in VEGF-induced angiogenesis during embryonic development and pathological disease states. The recombinant disulfide-linked homodimeric human VEGF is glycosylated and, thus, migrates as a ~42 kDa protein in SDS-PAGE under non-reducing conditions. Useful for proliferation assays; titrate for optimal results with individual cell types.
          FormLyophilized
          FormulationCarrier free.
          Purity≥95% by SDS-PAGE
          ContaminantsEndotoxins: ≤100 pg/µg VEGF
          Biological activityEC₅₀ of 1-6 ng/ml as determined by the dose dependent proliferation of human ubilical vein epithelial cells (HUVEC)
          SolubilityReconstitute lyophilized product in sterile PBS containing at least 0.1% human serum albumin or bovine serum albumin to ≥ 10 µg/ml. Make further dilutions in PBS, 0.1% BSA, HSA, or other carrier protein.
          PreservativeNone
          Storage -20°C
          Avoid freeze/thaw
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesHashimoto, G., et al. 2002. J. Biol. Chem. In Press.
          Soker, S., et al. 1998. Cell 92, 735.
          Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
          Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
          Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
          Brown, L., et al. 1992. Kidney International 42, 1457.
          Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275.
          Conn, G., et al. 1990. PNAS 87, 1323.
          Leung, D.W., et al. 1989. Science 246, 1306.